| 股號 / 名稱 | 現金及約當現金 | 流動資產 | 總資產 |
| TMO 賽默飛世爾科技 | 177,288,948,289.06 | 831,579,639,337.9 | 3,708,523,792,328.18 |
| LH Labcorp Holdings Inc. | 4,603,474,247.83 | 123,849,040,254.15 | 601,642,918,215.96 |
| DGX 奎斯特診斷 | 25,874,252,295.62 | 101,192,025,602.82 | 559,072,144,018.66 |
| A 安捷倫 | 57,072,692,014.68 | 152,356,168,159.78 | 453,432,474,043.82 |
| BIO Bio-Rad Laboratories, Inc. | 16,784,176,206.82 | 98,059,195,807.93 | 332,826,643,079.92 |
| ILMN Illumina Inc | 33,763,139,758.4 | 92,004,555,841.64 | 215,889,307,109.0 |
| QGEN QIAGEN N.V. | 24,949,012,408.01 | 53,781,662,431.29 | 191,190,336,722.55 |
| NTRA Natera, Inc. | 35,435,129,396.7 | 53,857,077,598.27 | 86,274,464,056.28 |
| TEM Tempus AI, Inc. | 19,466,203,156.82 | 41,907,360,965.6 | 76,808,253,604.75 |
| GH Guardant Health, Inc. | 34,200,404,882.83 | 44,302,401,227.66 | 62,081,778,443.41 |
| VCYT Veracyte, Inc. | 9,723,816,714.98 | 18,659,816,014.07 | 48,254,214,413.59 |
| NEO NeoGenomics, Inc. | 4,724,859,228.17 | 12,384,514,450.73 | 43,899,970,573.38 |
| BLLN BillionToOne, Inc. | 17,810,965,230.16 | 21,146,633,580.06 | 23,689,257,720.33 |
| CSTL Castle Biosciences, Inc. | 2,016,568,451.19 | 11,073,660,549.61 | 18,218,362,961.73 |
| 4169 泰宗 | 896,730,000 | 1,561,198,000 | 2,104,265,000 |
| 6598 ABC-KY | 449,173,000 | 934,031,000 | 1,073,322,000 |
載入數據中...
和癌症診斷相關的產業概念股
癌症診斷概念股相關指標排名
癌症診斷每月營收
癌症診斷每股盈餘
癌症診斷每股淨值
癌症診斷損益表
癌症診斷總資產
癌症診斷負債和股東權益
癌症診斷現金流量表
癌症診斷利潤比率
癌症診斷營業費用率拆解
癌症診斷杜邦分析
癌症診斷ROE / ROA
癌症診斷經營週轉能力
癌症診斷營運週轉天數
癌症診斷現金股利發放率
癌症診斷財務結構比率
癌症診斷流速動比率
癌症診斷利息保障倍數
癌症診斷現金流量分析
癌症診斷營業現金流對淨利比
癌症診斷盈餘再投資比率
癌症診斷月營收成長率
癌症診斷營收成長率
癌症診斷毛利成長率
癌症診斷營業利益成長率
癌症診斷稅後淨利成長率
癌症診斷每股盈餘成長率
癌症診斷本益比評價
癌症診斷股價淨值比評價
癌症診斷現金股利殖利率
癌症診斷平均現金股息殖利率
癌症診斷董監持股比例
癌症診斷董監持股質押比例